AVG-233

Research use only, not for human use.

AVG-233 is an orally available RNA-dependent RNA polymerase (RdRp) inhibitor with antiviral activity that blocks respiratory syncytial virus and SARS-CoV-2 replication.AVG-233 is used in the study of respiratory syncytial virus infections.

AVG-233 is a potent, orally active RNA dependent RNA polymerase (RdRp) inhibitor. AVG-233 prevents initiation of the viral polymerase complex at the promoter. AVG-233 binding site is present in the L1-1749 fragment. AVG-233 has nanomolar activity against both RSV strains and clinical RSV isolates (EC50=0.14-0.31 μM). AVG-233 can be used for research of respiratory syncytial virus (RSV).

——

Animal Model:Female Balb/cJ mice with recRSV-mKate xenograft Dosage:50 and 100 mg/kg Administration:Oral gavage; once Result:Reduced in lung viral load of 0.89 log10 TCID50 (median tissue culture infectious dose)/mL.Animal Model:Male CD-1 mice (27-29 g)Dosage:2 mg/kg (i.v.) and 20 mg/kg (p.o.) Administration:Intravenous injection and oral administration.

——

Cell Cycle/DNA Damage

DNA/RNA Synthesis

DNA/RNA Synthesis | RSV

——

——

2151937-80-1

487.94

C26H22ClN5O3

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (102.47 mM; Ultrasonic (<60°C)

COc1ccc(Cn2n(-c3ccccn3)c(=O)c3c(C)n(Cc4cccc(Cl)n4)c(=O)cc23)cc1

——

(-20℃)

With Ice Pack

≥ 2 years